87.3%; HR, 0.82; 95% CI, 0.69–0.98;P= .0260).[96][Level of evidence B1] The frequency of adverse events was similar in the two groups.
TheD-CAREtrial (NCT01077154) randomly assigned 4,509 women with stage II or stage III breast cancer to receive denosumab or placebo.[97]The primary end point of bone metastasis–free survival was not significantly different between the groups (median, not reached in either group; HR, 0.97; 95% CI, 0.82−1.14;P= .70).[97][Level of evidence B1] The primary end point of bone metastasis–free survival was not significantly different between the groups (median, not reached in either group; HR, 0.97; 95% CI, 0.82−1.14;P= .70).[97][Level of evidence B1] TheSUCCESStrial (NCT02181101) included 3,421 patients with node-positive or high-risk (≥pT2, grade 3, hormone receptor–negative, or aged 35 years or younger) node-negative breast cancer who completed adjuvant chemotherapy.